Filip Glista
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Filip Glista has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Agnieszka Dąbrowska
Szpital Wojewódzki w Poznaniu, Poznań, Poland
9 shared publications - Anna-Maria Grzeczka
Wielospecjalistyczny Szpital Miejski im. Józefa Strusia, Poznań, Poland
9 shared publications - Inez Michalska
Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland
9 shared publications - Katarzyna Pinkowska
Medical Center HCP, Poznań, Poland
9 shared publications - Mikołaj Jaszowski
Szpital Uniwersytecki nr 2 im. dr. Jana Biziela, Bydgoszcz, Poland
9 shared publications - Patrycja Pietraszkiewicz
Poznan University of Medical Sciences, Poznan, Poland
9 shared publications
Latest Publications
- Open Access
- 20 September 2026
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 26 (10) , 113
Genetic and Molecular Determinants of Cancer Therapy-Related Cardiovascular Toxicity
- 20 September 2026
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 26 (10) , 113
Open AccessGenetic and Molecular Determinants of Cancer Therapy-Related Cardiovascular Toxicity
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
CARDIOVASCULAR AND METABOLIC IMPLICATIONS OF E-CIGARETTE EXPOSURE: A COMPREHENSIVE REVIEW OF CURRENT EVIDENCE
Electronic cigarettes (e-cigarettes) have surged in global popularity as perceived safer alternatives to combustible tobacco, yet growing evidence identifies them as an independent cardiovascular and metabolic risk factor. To synthesize current knowledge, a systematic review was conducted across major databases (PubMed, Web of Science, Scopus) for high-quality studies published between 2016 and early 2026, including large-scale epidemiological data from the BRFSS and the Korean Community Health Survey. The analysis reveals that e-cigarette exposure induces acute adverse hemodynamic responses, significantly elevating blood pressure, heart rate, and cardiac workload, while chronic use leads to sustained autonomic imbalance with sympathetic predominance. At the vascular level, vaping exacerbates oxidative stress, increases arterial stiffness, and promotes a pro-inflammatory and pro-thrombotic environment. Crucially, across all cardiometabolic parameters, the most detrimental health outcomes are consistently observed among "dual users" who concurrently use both e-cigarettes and traditional combustible tobacco. Ultimately, this review refutes the narrative that e-cigarettes are a benign harm-reduction tool, concluding that they pose a significant, documented threat to cardiovascular and metabolic health. Consequently, clinical and public health prevention strategies must strongly advocate for the total cessation of all forms of nicotine delivery to protect long-term cardiovascular well-being.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessCARDIOVASCULAR AND METABOLIC IMPLICATIONS OF E-CIGARETTE EXPOSURE: A COMPREHENSIVE REVIEW OF CURRENT EVIDENCE
Electronic cigarettes (e-cigarettes) have surged in global popularity as perceived safer alternatives to combustible tobacco, yet growing evidence identifies them as an independent cardiovascular and metabolic risk factor. To synthesize current knowledge, a systematic review was conducted across major databases (PubMed, Web of Science, Scopus) for high-quality studies published between 2016 and early 2026, including large-scale epidemiological data from the BRFSS and the Korean Community Health Survey. The analysis reveals that e-cigarette exposure induces acute adverse hemodynamic responses, significantly elevating blood pressure, heart rate, and cardiac workload, while chronic use leads to sustained autonomic imbalance with sympathetic predominance. At the vascular level, vaping exacerbates oxidative stress, increases arterial stiffness, and promotes a pro-inflammatory and pro-thrombotic environment. Crucially, across all cardiometabolic parameters, the most detrimental health outcomes are consistently observed among "dual users" who concurrently use both e-cigarettes and traditional combustible tobacco. Ultimately, this review refutes the narrative that e-cigarettes are a benign harm-reduction tool, concluding that they pose a significant, documented threat to cardiovascular and metabolic health. Consequently, clinical and public health prevention strategies must strongly advocate for the total cessation of all forms of nicotine delivery to protect long-term cardiovascular well-being.
- Open Access
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
THE ROLE OF PHYSICAL ACTIVITY IN REDUCING PAIN IN PRIMARY DYSMENORRHEA: A NARRATIVE REVIEW
Background: Primary dysmenorrhea is one of the most common gynecological disorders among women of reproductive age, often associated with significant limitations in daily functioning. First-line treatment of primary dysmenorrhea is based on the use of NSAIDs, which may be associated with various side effects. To avoid pharmacological methods there is growing interest in alternative methods of pain reduction, including physical activity. Aim: The aim of this narrative review was to assess the current scientific evidence on the effects of various forms of physical activity on pain intensity in primary dysmenorrhea. Material and methods: A narrative literature review was conducted using PubMed and Google Scholar databases. Studies published mainly between 2016 and 2026 were analyzed, focusing on clinical trials, controlled clinical trials, randomized controlled trials, clinical studies, observational studies, and reviews. Results: Most of the studies analyzed showed a significant reduction in pain intensity after regular aerobic exercise, Pilates, stretching, yoga, and HIIT training. In addition, some studies have observed an improvement in quality of life and functioning, as well as a reduction in premenstrual symptoms. However, a study on Zumba did not show a statistically significant reduction in pain. Conclusions: Regular physical activity plays an important role in the non-pharmacological treatment of primary dysmenorrhea. Appropriately selected exercises can effectively contribute to reducing pain and improving the quality of life among women struggling with this disease. Physical exercise should be considered a supportive element of standard therapeutic strategies in the treatment of primary dysmenorrhea.
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
Open AccessTHE ROLE OF PHYSICAL ACTIVITY IN REDUCING PAIN IN PRIMARY DYSMENORRHEA: A NARRATIVE REVIEW
Background: Primary dysmenorrhea is one of the most common gynecological disorders among women of reproductive age, often associated with significant limitations in daily functioning. First-line treatment of primary dysmenorrhea is based on the use of NSAIDs, which may be associated with various side effects. To avoid pharmacological methods there is growing interest in alternative methods of pain reduction, including physical activity. Aim: The aim of this narrative review was to assess the current scientific evidence on the effects of various forms of physical activity on pain intensity in primary dysmenorrhea. Material and methods: A narrative literature review was conducted using PubMed and Google Scholar databases. Studies published mainly between 2016 and 2026 were analyzed, focusing on clinical trials, controlled clinical trials, randomized controlled trials, clinical studies, observational studies, and reviews. Results: Most of the studies analyzed showed a significant reduction in pain intensity after regular aerobic exercise, Pilates, stretching, yoga, and HIIT training. In addition, some studies have observed an improvement in quality of life and functioning, as well as a reduction in premenstrual symptoms. However, a study on Zumba did not show a statistically significant reduction in pain. Conclusions: Regular physical activity plays an important role in the non-pharmacological treatment of primary dysmenorrhea. Appropriately selected exercises can effectively contribute to reducing pain and improving the quality of life among women struggling with this disease. Physical exercise should be considered a supportive element of standard therapeutic strategies in the treatment of primary dysmenorrhea.
- Open Access
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS): CLINICAL PRESENTATION, DIAGNOSIS, PATHOPHYSIOLOGY AND TREATMENT OPTIONS – A LITERATURE REVIEW
Introduction: Postural orthostatic tachycardia syndrome (POTS) is a chronic disorder of the autonomic nervous system characterised by orthostatic intolerance and an excessive increase in heart rate (≥30 beats per minute) upon standing, in the absence of orthostatic hypotension. Patients often experience additional symptoms such as fatigue, dizziness and palpitations. The disorder predominantly affects young women. Although the aetiology remains unclear, several mechanisms have been proposed. Due to its complex clinical presentation and limited awareness among healthcare professionals, POTS is frequently misdiagnosed. Aim: The aim of this review is to summarise the current knowledge regarding the aetiology, clinical presentation, diagnosis and treatment of postural orthostatic tachycardia syndrome. Materials and methods: This review is based on literature available in the PubMed database. Articles were identified using keywords including postural orthostatic tachycardia syndrome, POTS, orthostatic intolerance and tachycardia, and the most relevant publications were analysed. Results: POTS remains a moderately understood disorder. The prevalence is estimated at approximately 0.2% of the general population, with women of reproductive age accounting for up to 90% of cases. The pathophysiology is multifactorial and includes three main mechanisms: partial autonomic neuropathy, hypovolemia and a hyperadrenergic state. Management includes both non-pharmacological interventions, such as increased fluid intake and lifestyle modification, and pharmacological therapies including beta-blockers and ivabradine. Conclusions: POTS remains a diagnostic and therapeutic challenge. Increased awareness and further research are essential to improve diagnosis and patient outcomes.
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
Open AccessPOSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS): CLINICAL PRESENTATION, DIAGNOSIS, PATHOPHYSIOLOGY AND TREATMENT OPTIONS – A LITERATURE REVIEW
Introduction: Postural orthostatic tachycardia syndrome (POTS) is a chronic disorder of the autonomic nervous system characterised by orthostatic intolerance and an excessive increase in heart rate (≥30 beats per minute) upon standing, in the absence of orthostatic hypotension. Patients often experience additional symptoms such as fatigue, dizziness and palpitations. The disorder predominantly affects young women. Although the aetiology remains unclear, several mechanisms have been proposed. Due to its complex clinical presentation and limited awareness among healthcare professionals, POTS is frequently misdiagnosed. Aim: The aim of this review is to summarise the current knowledge regarding the aetiology, clinical presentation, diagnosis and treatment of postural orthostatic tachycardia syndrome. Materials and methods: This review is based on literature available in the PubMed database. Articles were identified using keywords including postural orthostatic tachycardia syndrome, POTS, orthostatic intolerance and tachycardia, and the most relevant publications were analysed. Results: POTS remains a moderately understood disorder. The prevalence is estimated at approximately 0.2% of the general population, with women of reproductive age accounting for up to 90% of cases. The pathophysiology is multifactorial and includes three main mechanisms: partial autonomic neuropathy, hypovolemia and a hyperadrenergic state. Management includes both non-pharmacological interventions, such as increased fluid intake and lifestyle modification, and pharmacological therapies including beta-blockers and ivabradine. Conclusions: POTS remains a diagnostic and therapeutic challenge. Increased awareness and further research are essential to improve diagnosis and patient outcomes.
- Open Access
- 25 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
THE ROLE OF MYOGENIC DIFFERENTIATION ABERRATIONS IN THE PHYSICAL PERFORMANCE
Physical performance is influenced by numerous factors, both congenital and non-congenital. Key determinants include diet, physical activity, lifestyle, and environmental exposure. It depends largely on the proper functioning of the musculoskeletal and cardiovascular systems. Human myogenesis is a tightly regulated process that begins during prenatal development and continues throughout life. The key regulators of this process are myogenic regulatory factors (MRFs), a family of helix–loop–helix transcription factors. These factors cooperate with members of the myocyte enhancer factor 2 (MEF2) family to promote the transcription of muscle-specific genes. In addition, epigenetic mechanisms play a crucial role in regulating gene expression during myogenic differentiation and satellite cell activation. Cell-cycle regulators further contribute to myogenesis by controlling satellite cell proliferation and differentiation, thereby influencing muscle regeneration. Moreover, a wide range of bioactive compounds has been shown to modulate myogenesis through their effects on key regulatory pathways. These regulatory mechanisms may contribute to interindividual variability in physical performance. However, most of the available evidence is derived from in vitro studies, and its relevance to human physiology remains uncertain. Therefore, further research is required to better understand the role of these mechanisms in shaping physical performance. The aim of this review is to summarize current knowledge on the regulatory mechanisms of myogenesis and their role in physical performance. A narrative review of recent literature focusing on molecular and cellular mechanisms regulating myogenesis was conducted.
- 25 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
Open AccessTHE ROLE OF MYOGENIC DIFFERENTIATION ABERRATIONS IN THE PHYSICAL PERFORMANCE
Physical performance is influenced by numerous factors, both congenital and non-congenital. Key determinants include diet, physical activity, lifestyle, and environmental exposure. It depends largely on the proper functioning of the musculoskeletal and cardiovascular systems. Human myogenesis is a tightly regulated process that begins during prenatal development and continues throughout life. The key regulators of this process are myogenic regulatory factors (MRFs), a family of helix–loop–helix transcription factors. These factors cooperate with members of the myocyte enhancer factor 2 (MEF2) family to promote the transcription of muscle-specific genes. In addition, epigenetic mechanisms play a crucial role in regulating gene expression during myogenic differentiation and satellite cell activation. Cell-cycle regulators further contribute to myogenesis by controlling satellite cell proliferation and differentiation, thereby influencing muscle regeneration. Moreover, a wide range of bioactive compounds has been shown to modulate myogenesis through their effects on key regulatory pathways. These regulatory mechanisms may contribute to interindividual variability in physical performance. However, most of the available evidence is derived from in vitro studies, and its relevance to human physiology remains uncertain. Therefore, further research is required to better understand the role of these mechanisms in shaping physical performance. The aim of this review is to summarize current knowledge on the regulatory mechanisms of myogenesis and their role in physical performance. A narrative review of recent literature focusing on molecular and cellular mechanisms regulating myogenesis was conducted.
- Open Access
- 15 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
OVERPRESCRIPTION OF PROTON PUMP INHIBITORS: CAUSES, CONSEQUENCES AND STRATEGIES FOR RATIONAL USE
Background. Proton pump inhibitors (PPIs) are effective medications widely used to manage acid-related disorders. However, their perceived safety has led to a global trend of overprescription. Therapy is often initiated during hospital stays for stress ulcer prophylaxis and continued indefinitely in primary care without a clear medical indication. Aim. This narrative review aims to examine the clinical predictors and causes of PPI overuse, explore the medical consequences of long-term acid suppression, and discuss evidence-based strategies to promote rational use in clinical practice. Material and Methods. The literature for this narrative review was selected from PubMed-indexed publications published between 2010 and 2026. ACG and AGA clinical guidelines, systematic reviews, and observational studies were analyzed to describe the predictors of PPI overuse, its medical consequences and evidence-based strategies for deprescribing. Results. PPI overuse is primarily driven by prescribing inertia. Patient education significantly improves the success of dose reduction. While clinical decision support systems effectively reduce the initiation of inappropriate therapy, clinician acceptance of deprescribing alerts remains low compared to initiation prompts. In contrast, multidisciplinary models integrating artificial intelligence with pharmacist oversight achieve high rates of rational prescribing. Conclusions. Given the massive global economic burden, PPI optimization requires a synergy of digital tools, patient education, and pharmacist-led oversight. This integrated strategy is essential for ensuring systemic sustainability and long-term medication safety.
- 15 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
Open AccessOVERPRESCRIPTION OF PROTON PUMP INHIBITORS: CAUSES, CONSEQUENCES AND STRATEGIES FOR RATIONAL USE
Background. Proton pump inhibitors (PPIs) are effective medications widely used to manage acid-related disorders. However, their perceived safety has led to a global trend of overprescription. Therapy is often initiated during hospital stays for stress ulcer prophylaxis and continued indefinitely in primary care without a clear medical indication. Aim. This narrative review aims to examine the clinical predictors and causes of PPI overuse, explore the medical consequences of long-term acid suppression, and discuss evidence-based strategies to promote rational use in clinical practice. Material and Methods. The literature for this narrative review was selected from PubMed-indexed publications published between 2010 and 2026. ACG and AGA clinical guidelines, systematic reviews, and observational studies were analyzed to describe the predictors of PPI overuse, its medical consequences and evidence-based strategies for deprescribing. Results. PPI overuse is primarily driven by prescribing inertia. Patient education significantly improves the success of dose reduction. While clinical decision support systems effectively reduce the initiation of inappropriate therapy, clinician acceptance of deprescribing alerts remains low compared to initiation prompts. In contrast, multidisciplinary models integrating artificial intelligence with pharmacist oversight achieve high rates of rational prescribing. Conclusions. Given the massive global economic burden, PPI optimization requires a synergy of digital tools, patient education, and pharmacist-led oversight. This integrated strategy is essential for ensuring systemic sustainability and long-term medication safety.
- Open Access
- 11 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
ADHD IN ELITE ATHLETES: PHARMACOLOGICAL TREATMENT, TUE AND STIMULANT MISUSE RISK
Background. Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental condition that frequently persists into adolescence and adulthood, affecting attention regulation, impulsivity, emotional control, sleep and overall functioning. In elite/competitive sport, these domains are tightly linked to training adherence, tactical decision-making, injury risk and recovery. Pharmacotherapy is one of the most effective evidence-based treatments for ADHD, yet in high-performance sport it must be implemented within additional constraints: potential cardiovascular and sleep-related adverse effects under heavy training load, elevated risk of non-medical use and diversion of prescription stimulants in athlete-adjacent environments and anti-doping regulations that may require a Therapeutic Use Exemption (TUE) for prohibited stimulant medications. Aim: To summarize evidence and practical guidance on pharmacological treatment of ADHD in elite/competitive athletes with specific focus on medication selection and monitoring under high training demands, TUE and anti-doping compliance, and prevention and management of stimulant misuse/diversion risk. Materials and Methods: A narrative literature review was conducted using a structured search strategy in PubMed/MEDLINE, supplemented by targeted retrieval of relevant World Anti-Doping Agency (WADA) TUE/ISTUE documents. The search covered the period from January 2011 to January 2026. The final search was executed on 16 February 2026. Eligible publications included original research, systematic reviews/meta-analyses, and regulatory guidance addressing ADHD pharmacotherapy, athlete contexts, TUE/anti-doping implications, and/or stimulant misuse/diversion. Results: The evidence supports that core pharmacotherapy principles for ADHD are broadly similar in athletes and non-athletes; however, elite sport requires additional implementation safeguards. Stimulants remain highly effective for symptom control but warrant careful monitoring of heart rate/blood pressure, sleep, appetite/energy availability, and anxiety—particularly during titration and high-load training periods. Non-stimulants (e.g., atomoxetine; selected cases guanfacine) may be appropriate when stimulants are not tolerated, contraindicated or when misuse/diversion risk is high. In tested sport, clinically necessary stimulant use often necessitates early, well-documented TUE planning to avoid inconsistencies between prescribing and regulatory submissions. Misuse and diversion are most commonly documented in young adult and collegiate settings, where sport-relevant drivers such as performance pressure, peer “sharing,” and weight-control motives may be present; this highlights the need for proactive education, secure storage, and structured follow-up. Conclusions: ADHD pharmacotherapy can be appropriate and beneficial in elite athletes, but it must be embedded in a sport-specific framework that integrates safety monitoring, stable competition-period planning, anti-doping/TUE documentation, and misuse/diversion risk mitigation. High-quality athlete-specific comparative studies - particularly stimulant versus non-stimulant strategies using objective outcomes - remain a key research priority.
- 11 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
Open AccessADHD IN ELITE ATHLETES: PHARMACOLOGICAL TREATMENT, TUE AND STIMULANT MISUSE RISK
Background. Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental condition that frequently persists into adolescence and adulthood, affecting attention regulation, impulsivity, emotional control, sleep and overall functioning. In elite/competitive sport, these domains are tightly linked to training adherence, tactical decision-making, injury risk and recovery. Pharmacotherapy is one of the most effective evidence-based treatments for ADHD, yet in high-performance sport it must be implemented within additional constraints: potential cardiovascular and sleep-related adverse effects under heavy training load, elevated risk of non-medical use and diversion of prescription stimulants in athlete-adjacent environments and anti-doping regulations that may require a Therapeutic Use Exemption (TUE) for prohibited stimulant medications. Aim: To summarize evidence and practical guidance on pharmacological treatment of ADHD in elite/competitive athletes with specific focus on medication selection and monitoring under high training demands, TUE and anti-doping compliance, and prevention and management of stimulant misuse/diversion risk. Materials and Methods: A narrative literature review was conducted using a structured search strategy in PubMed/MEDLINE, supplemented by targeted retrieval of relevant World Anti-Doping Agency (WADA) TUE/ISTUE documents. The search covered the period from January 2011 to January 2026. The final search was executed on 16 February 2026. Eligible publications included original research, systematic reviews/meta-analyses, and regulatory guidance addressing ADHD pharmacotherapy, athlete contexts, TUE/anti-doping implications, and/or stimulant misuse/diversion. Results: The evidence supports that core pharmacotherapy principles for ADHD are broadly similar in athletes and non-athletes; however, elite sport requires additional implementation safeguards. Stimulants remain highly effective for symptom control but warrant careful monitoring of heart rate/blood pressure, sleep, appetite/energy availability, and anxiety—particularly during titration and high-load training periods. Non-stimulants (e.g., atomoxetine; selected cases guanfacine) may be appropriate when stimulants are not tolerated, contraindicated or when misuse/diversion risk is high. In tested sport, clinically necessary stimulant use often necessitates early, well-documented TUE planning to avoid inconsistencies between prescribing and regulatory submissions. Misuse and diversion are most commonly documented in young adult and collegiate settings, where sport-relevant drivers such as performance pressure, peer “sharing,” and weight-control motives may be present; this highlights the need for proactive education, secure storage, and structured follow-up. Conclusions: ADHD pharmacotherapy can be appropriate and beneficial in elite athletes, but it must be embedded in a sport-specific framework that integrates safety monitoring, stable competition-period planning, anti-doping/TUE documentation, and misuse/diversion risk mitigation. High-quality athlete-specific comparative studies - particularly stimulant versus non-stimulant strategies using objective outcomes - remain a key research priority.
- Open Access
- 19 April 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 54
Obesity as a Risk Factor for Endometrial Cancer – Pathophysiological Mechanisms
Background. Endometrial cancer is the most common gynecological malignancy in developed countries. Obesity is a major modifiable risk factor, promoting inflammation, hyperinsulinemia, increased estrogen production, and metabolic disturbances that contribute to carcinogenesis. Aim. This narrative review summarizes current evidence on the pathophysiological mechanisms linking obesity with endometrial cancer and highlights the relevance of molecular classification and lifestyle-related prevention. Material and methods. A narrative analysis of open-access publications (2008–2026) was conducted, focusing on epidemiology, metabolic and hormonal pathways related to obesity, and molecular subtypes of endometrial cancer described by The Cancer Genome Atlas (TCGA). Results. Obesity contributes to endometrial cancer through estrogen excess, insulin resistance, IGF-1 signaling, chronic inflammation, and adipokine imbalance. Four molecular subtypes are recognized: POLE ultramutated, mismatch repair deficient, p53-abnormal, and non-specific profile. Physical activity may reduce cancer risk. Conclusions. Understanding obesity-related molecular pathways in endometrial cancer may improve risk stratification and treatment decisions. Preventive strategies, including weight control and regular physical activity, may reduce disease burden. Key words: endometrial cancer, obesity, molecular classification, TCGA, physical activity.
- 19 April 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 54
Open AccessObesity as a Risk Factor for Endometrial Cancer – Pathophysiological Mechanisms
Background. Endometrial cancer is the most common gynecological malignancy in developed countries. Obesity is a major modifiable risk factor, promoting inflammation, hyperinsulinemia, increased estrogen production, and metabolic disturbances that contribute to carcinogenesis. Aim. This narrative review summarizes current evidence on the pathophysiological mechanisms linking obesity with endometrial cancer and highlights the relevance of molecular classification and lifestyle-related prevention. Material and methods. A narrative analysis of open-access publications (2008–2026) was conducted, focusing on epidemiology, metabolic and hormonal pathways related to obesity, and molecular subtypes of endometrial cancer described by The Cancer Genome Atlas (TCGA). Results. Obesity contributes to endometrial cancer through estrogen excess, insulin resistance, IGF-1 signaling, chronic inflammation, and adipokine imbalance. Four molecular subtypes are recognized: POLE ultramutated, mismatch repair deficient, p53-abnormal, and non-specific profile. Physical activity may reduce cancer risk. Conclusions. Understanding obesity-related molecular pathways in endometrial cancer may improve risk stratification and treatment decisions. Preventive strategies, including weight control and regular physical activity, may reduce disease burden. Key words: endometrial cancer, obesity, molecular classification, TCGA, physical activity.
- Open Access
- 15 April 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
PERIOPERATIVE ANESTHETIC MANAGEMENT IN PATIENTS WITH HEART FAILURE: FROM RISK ASSESSMENT TO HEMODYNAMIC OPTIMIZATION, INTEGRATING FUNCTIONAL CAPACITY ASSESSMENT AND EXERCISE PREHABILITATION – A NARRATIVE REVIEW
Background: Heart failure (HF) increases perioperative complications and mortality in patients undergoing non-cardiac surgery. Both heart failure with reduced ejection fraction and preserved ejection fraction increase cardiovascular risk and require perioperative management. Aim: This review summarizes evidence on perioperative anesthetic management in patients with HF undergoing non-cardiac surgery, focusing on risk assessment, medical therapy optimization, intraoperative hemodynamic management, fluid therapy, postoperative monitoring and impact of exercise on recovery. Materials and Methods: This narrative review included PubMed-indexed studies published between 2021 and 2026. ESC consensus statements, randomized trials, and large cohort studies were analyzed to summarize practical recommendations for perioperative management of HF. Results: Preoperative evaluation should include clinical assessment, natriuretic peptide measurement, and echocardiography. Optimization of medical therapy and euvolemia is essential. During surgery, maintaining MAP ≥ 65 mmHg, careful fluid therapy, and early vasopressor use may reduce myocardial injury. Conclusions: Perioperative management of patients with heart failure should include risk assessment, prehabilitation, hemodynamic control, multidisciplinary care, and functional capacity evaluation to improve short-term outcomes.
- 15 April 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
Open AccessPERIOPERATIVE ANESTHETIC MANAGEMENT IN PATIENTS WITH HEART FAILURE: FROM RISK ASSESSMENT TO HEMODYNAMIC OPTIMIZATION, INTEGRATING FUNCTIONAL CAPACITY ASSESSMENT AND EXERCISE PREHABILITATION – A NARRATIVE REVIEW
Background: Heart failure (HF) increases perioperative complications and mortality in patients undergoing non-cardiac surgery. Both heart failure with reduced ejection fraction and preserved ejection fraction increase cardiovascular risk and require perioperative management. Aim: This review summarizes evidence on perioperative anesthetic management in patients with HF undergoing non-cardiac surgery, focusing on risk assessment, medical therapy optimization, intraoperative hemodynamic management, fluid therapy, postoperative monitoring and impact of exercise on recovery. Materials and Methods: This narrative review included PubMed-indexed studies published between 2021 and 2026. ESC consensus statements, randomized trials, and large cohort studies were analyzed to summarize practical recommendations for perioperative management of HF. Results: Preoperative evaluation should include clinical assessment, natriuretic peptide measurement, and echocardiography. Optimization of medical therapy and euvolemia is essential. During surgery, maintaining MAP ≥ 65 mmHg, careful fluid therapy, and early vasopressor use may reduce myocardial injury. Conclusions: Perioperative management of patients with heart failure should include risk assessment, prehabilitation, hemodynamic control, multidisciplinary care, and functional capacity evaluation to improve short-term outcomes.
- Open Access
- 30 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (1(49))
HEART FAILURE WITH PRESERVED EJECTION FRACTION: THE CENTRAL ROLE OF LIFESTYLE MODIFICATION AND NONPHARMACOLOGICAL THERAPIES
Introduction: Heart failure with preserved ejection fraction (HFpEF) is a condition characterized by significant morbidity and mortality, as well as a considerable burden on healthcare systems. Until recently, sodium-glucose co-transporter 2 (SGLT2) inhibitors were the only drug class to demonstrate a consistent benefit in clinical outcomes among these patients. HFpEF is a complex, multifactorial disorder frequently associated with advanced age, obesity, hypertension, diabetes, and sedentary lifestyle. Many of these risk factors are potentially modifiable. Aim of the Study: The aim of this article is to provide a comprehensive overview of the role of nonpharmacological interventions and lifestyle modifications in the management of HFpEF, emphasizing current evidence for their effectiveness and highlighting the importance of patient-centered, multidisciplinary approaches in improving clinical outcomes. Materials and Methods: A thorough review of the literature was conducted using the PubMed database, Google Scholar with search terms including “heart failure with preserved ejection fraction”, “HFpEF treatment”, “lifestyle modification”, “obesity”, “diet”, “exercise”, vagus nerve stimulation” and related keywords. Results and Conclusions: Nonpharmacological interventions, including exercise training, dietary modification, weight management, and patient education, have demonstrated significant benefits in improving functional capacity, quality of life, and cardiovascular risk profiles in patients with HFpEF. Although pharmacological treatment options remain limited, lifestyle-based strategies are essential components of comprehensive care for this population. Future research should continue to refine and personalize nonpharmacological approaches to further improve outcomes for individuals living with HFpEF.
- 30 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (1(49))
Open AccessHEART FAILURE WITH PRESERVED EJECTION FRACTION: THE CENTRAL ROLE OF LIFESTYLE MODIFICATION AND NONPHARMACOLOGICAL THERAPIES
Introduction: Heart failure with preserved ejection fraction (HFpEF) is a condition characterized by significant morbidity and mortality, as well as a considerable burden on healthcare systems. Until recently, sodium-glucose co-transporter 2 (SGLT2) inhibitors were the only drug class to demonstrate a consistent benefit in clinical outcomes among these patients. HFpEF is a complex, multifactorial disorder frequently associated with advanced age, obesity, hypertension, diabetes, and sedentary lifestyle. Many of these risk factors are potentially modifiable. Aim of the Study: The aim of this article is to provide a comprehensive overview of the role of nonpharmacological interventions and lifestyle modifications in the management of HFpEF, emphasizing current evidence for their effectiveness and highlighting the importance of patient-centered, multidisciplinary approaches in improving clinical outcomes. Materials and Methods: A thorough review of the literature was conducted using the PubMed database, Google Scholar with search terms including “heart failure with preserved ejection fraction”, “HFpEF treatment”, “lifestyle modification”, “obesity”, “diet”, “exercise”, vagus nerve stimulation” and related keywords. Results and Conclusions: Nonpharmacological interventions, including exercise training, dietary modification, weight management, and patient education, have demonstrated significant benefits in improving functional capacity, quality of life, and cardiovascular risk profiles in patients with HFpEF. Although pharmacological treatment options remain limited, lifestyle-based strategies are essential components of comprehensive care for this population. Future research should continue to refine and personalize nonpharmacological approaches to further improve outcomes for individuals living with HFpEF.